Drug Trial Radar · NCT03044743
PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies
Last checked: Nov 19, 2026Latest source record: May 2, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
20
Planned (sponsor's estimate)
Start
Apr 7, 2017
Primary completion
Mar 2020
Study completion Mar 2022
Sponsor
- Lead sponsor
- Yang YangAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 7, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety of PD-1 knockout EBV-CTL cells in treating EBV (Epstein-Barr virus) positive advanced stage malignancies. Blood samples will also be collected for research purposes.
Conditions
- Stage IV Gastric Carcinoma
- Stage IV Nasopharyngeal Carcinoma
- T-Cell Lymphoma Stage IV
- Stage IV Adult Hodgkin Lymphoma
- Stage IV Diffuse Large B-Cell Lymphoma
Interventions
FludarabineDrug
To modify immune micro-environment
CyclophosphamideDrug
To modify immune micro-environment
Interleukin-2Drug
To sustain the survival of infused T cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse Events using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patientsTime frame: 6 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The Comprehensive Cancer Center of Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Recruiting
The Comprehensive Cancer Center of Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.